The anti-steatosis effects of myeloid GPSM1 knockout were presumably attributed to downregulation of fatty acid uptake genes (CD36, FABP4) and upregulation of fatty acid β-oxidation genes (LCAD) in the liver (Supplementary Fig. 3h). The gene discussed is FABP4; the disease is steatosis.